Dr. Christian Gisselbrecht on Defining Refractory Disease in DLBCL

Christian Gisselbrecht, MD
Published: Saturday, Jun 11, 2016



Christian Gisselbrecht, MD, a Professor of Haematology in the Haemato-Oncology Department of Hôpital Saint-Louis, at Diderot University, Paris, discusses stratifying refractory disease in aggressive diffuse large b-cell lymphoma (DLBCL).
 
Instead of just assuming a patient is refractory because they’ve relapsed, Gisselbrecht’s team wanted a more precise definition.
 
In collaboration with several companies and cancer centers, Gisselbrecht’s team determined several types of refractory patients.
 
By defining different groups of relapsed patients, prognostic factors can be determined for specific populations, says Gisselbrecht.

<<< View more from the 2016 EHA Congress


Christian Gisselbrecht, MD, a Professor of Haematology in the Haemato-Oncology Department of Hôpital Saint-Louis, at Diderot University, Paris, discusses stratifying refractory disease in aggressive diffuse large b-cell lymphoma (DLBCL).
 
Instead of just assuming a patient is refractory because they’ve relapsed, Gisselbrecht’s team wanted a more precise definition.
 
In collaboration with several companies and cancer centers, Gisselbrecht’s team determined several types of refractory patients.
 
By defining different groups of relapsed patients, prognostic factors can be determined for specific populations, says Gisselbrecht.

<<< View more from the 2016 EHA Congress

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x